This differs from what has been recently described in other prostate cancer models of lineage plasticity in which EZH2 inhibition resulted in re-expression of the AR26,28, possibly due to an earlier more “plastic” disease state in those models where AR was not completely absent prior to therapy. This evidence concerns the gene EZH2 and Familial prostate cancer.